Alterations of Immunologic Mediators During Severe Sepsis

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00484146

Acronym

LAVISS_01

Enrollment

Registered

2007-06-08

Start date

2006-06-30

Completion date

2012-12-31

Last updated

2017-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Sepsis

Keywords

Sepsis, Early Stage, Immune System, Receptors, Cytokines

Brief summary

Severe sepsis induces significant changes in expression of insulin- and toll-like receptors, cytokines, markers of apoptosis, and activation of t- and b-lymphocytes.

Detailed description

In patients at early stage of severe sepsis, we investigate the expression of pro- and anti-inflammatory cytokines, chemokines, adhesion-molecules, toll-like receptors, insulin-receptors, markers of apoptosis und of t- and b-cell-activation on a mRNA level.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* age \>= 18 y * agreement with study procedures * 3 of 4 SIRS-criteria * proven or highly suspected infection * 2 or more sepsis-induced organ failures * start of first sepsis-induced organ failure within the last 36 hours

Exclusion criteria

* non-agreement with study procedures * signs of severe sepsis with organ failure \> 36 hours * chronic immuno-compromising diseases * chronic therapy with anti-inflammatory drugs * non-curable cancer * chronic renal failure with hemodialysis * pregnancy or breast-feeding

Design outcomes

Primary

Measure	Time frame	Description
severity of sepsis	96 hours after diagnosis of sepsis	SOFA-Score

Countries

Germany

Outcome results